Funding Details
- Awarder
- Inbox
- Date Award
- May 23, 2024
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Valuation
-
$99,000,000
Company Info
- Traction
- Initial data on the ongoing adaptive Phase 1/2 trial of the lead asset GRWD5769, a first-in-class ERAP1 inhibitor will be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) annual meeting. A second ERAP1 inhibitor focused on autoimmune disease is being advanced through IND-enabling studies with the goal of entering the clinic in 2025.
- Organizations Involved
- ICG, Pfizer Ventures, Andera Partners, Canaan, Earlybird Venture Capital, Oxford Science Enterprises, British Patient Capital
- Company Description
- Grey Wolf Therapeutics is a clinical-stage, UK- and Australian-based drug discovery and development biotechnology company spearheading a new therapeutic approach based on a first-of-its-kind antigen modulation platform. The company’s lead clinical development candidate, GRWD5769, is a potent and selective oral ERAP1 inhibitor that has shown the potential to elicit a powerful and differentiated immune response against tumors. A second ERAP1 inhibitor, GRWD0715, is advancing through preclinical development as a potential treatment for autoimmune disease. The company is also leveraging its leadership in neoantigen creation with an ERAP2 drug discovery program and by therapeutically targeting novel ERAP1 inhibitor generated cancer antigens with MHC Class I directed therapies, such as soluble T cell receptor (TCR) and TCR mimic bispecifics.
- Market
- Oncology and Autoimmunity
- Location
-
Oxford,
UK
- Coinvestors
- ICG’s Life Sciences team, Pfizer Ventures, Andera Partners, Canaan, Earlybird Venture Capital, Oxford Science Enterprises, British Patient Capital
Links